Characterization of Vascular Effects of Angiotensin II in Dorsal Human Hand Veins.

This study has been completed.

Sponsored by:	Dresden University of Technology
Information provided by:	Dresden University of Technology
ClinicalTrials.gov Identifier:	NCT00180024

Purpose

The hypothesis is tested that stimulation with angiotensin II after blockade of the AT1-receptor results in venodilation in human healthy subjects in vivo.

Condition	Intervention
Healthy Subjects	Drug: irbesartan (drug)

Drug Information available for: Irbesartan Angiotensin II Angiotensin II, ile(5)-

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Educational/Counseling/Training, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study

Further study details as provided by Dresden University of Technology:

Study Start Date:	January 2002
Estimated Study Completion Date:	September 2005

Eligibility

Ages Eligible for Study:	18 Years to 45 Years
Genders Eligible for Study:	Male
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

healthy subjects

Exclusion Criteria:

any relevant disease

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00180024

Locations

Germany
Institute of Clinical Pharmacology, Medical Faculty, University of Technology
Dresden, Germany, 01307

Sponsors and Collaborators

Dresden University of Technology

Investigators

Study Chair:

Wilhelm Kirch, MD

Institute of Clinical Pharmacology

More Information

Study ID Numbers:	IKPD 01-02
Study First Received:	September 9, 2005
Last Updated:	September 9, 2005
ClinicalTrials.gov Identifier:	NCT00180024
Health Authority:	Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by Dresden University of Technology:

AT1-receptor
AT2-receptor
human pharmacology

Study placed in the following topic categories:

Ataxia-Telangiectasia
Irbesartan
Healthy
Ataxia Telangiectasia
Angiotensin II

ClinicalTrials.gov processed this record on January 16, 2009